Regenxbio Inc., was founded on July 16, 2008. The company is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus gene therapies. In AAV gene therapy, viral genes are removed from AAV (a small, non-pathogenic cold virus) to build a biological delivery tool called a vector. The therapeutic gene sequence is then inserted into it to form a recombinant vector. The company has a proprietary AAV gene delivery platform that contains exclusive rights to over 100 new AAV vectors, including AAV7, AAV8, AAV9 and AAVrh 10. The company's mission is to develop and commercialize gene therapy products that are injected directly into the body (i.e., administered in vivo) based on its NAV technology platform, thereby improving the lives of patients with serious diseases and significant unmet medical needs.
